These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 35993)

  • 21. The case for long-acting antipsychotic agents in the post-CATIE era.
    Nasrallah HA
    Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of depot neuroleptics on pituitary hormone secretion (author's transl)].
    Czernik A; Kleesiek K
    Nervenarzt; 1979 Aug; 50(8):527-33. PubMed ID: 43482
    [No Abstract]   [Full Text] [Related]  

  • 24. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
    Ezrin-Waters C; Seeman MV; Seeman P
    J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukopenia during therapy with risperidone long-acting injectable: two case reports.
    Uzun S; Kozumplik O; Jakovljević M; Folnegović-Smalc V
    J Clin Psychopharmacol; 2008 Dec; 28(6):713-4. PubMed ID: 19011449
    [No Abstract]   [Full Text] [Related]  

  • 26. [Prevalence of depressive symptoms in a population of ambulatory schizophrenics].
    Lempérière T; Rodière C; Rousselet N; Pilate C; Ades J; Lépine JP; Rouillon F
    Ann Med Psychol (Paris); 1983 Feb; 141(2):224-36. PubMed ID: 6137178
    [No Abstract]   [Full Text] [Related]  

  • 27. Depot neuroleptic therapy: clinical considerations.
    Remington GJ; Adams ME
    Can J Psychiatry; 1995 Apr; 40(3 Suppl 1):S5-11. PubMed ID: 7627927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The long-term treatment of schizophrenia in the community.
    Rollin HR
    Practitioner; 1982 Jul; 226(1369):1330-3. PubMed ID: 6125936
    [No Abstract]   [Full Text] [Related]  

  • 29. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
    Gutwinski S; Müller P; Koller M
    Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
    Lai YC; Chiou CC; Chen CH; Huang MC
    J Clin Psychopharmacol; 2007 Oct; 27(5):523-4. PubMed ID: 17873693
    [No Abstract]   [Full Text] [Related]  

  • 32. [Longterm therapy of schizophrenia].
    Pajonk FG; Wobrock T; Falkai P
    Fortschr Neurol Psychiatr; 2005 Mar; 73(3):161-74; quiz 175-7. PubMed ID: 15747226
    [No Abstract]   [Full Text] [Related]  

  • 33. Longterm maintenance therapy with depot haloperidol in schizophrenia.
    Zbytovský J
    Homeost Health Dis; 1991; 33(5-6):287. PubMed ID: 18265499
    [No Abstract]   [Full Text] [Related]  

  • 34. [Schizophrenia: prophylaxis prevents recurrence. Low dose depot neuroleptics--an exit from the "revolving door" psychiatry].
    Fortschr Med Suppl; 1993; 147():1-15. PubMed ID: 9260317
    [No Abstract]   [Full Text] [Related]  

  • 35. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monthly intermittent chemotherapy of chronic schizophrenic outpatients with pipothiazine palmitate.
    Laurent JS; Carle R; Dumais B; Domingue D
    Can Psychiatr Assoc J; 1974 Dec; 19(6):583-91. PubMed ID: 4155349
    [No Abstract]   [Full Text] [Related]  

  • 37. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mortality among chronic schizophrenic patients: a prospective 14-year follow-up study of 150 schizophrenic patients].
    Loas G; Azi A; Noisette C; Yon V
    Encephale; 2008 Jan; 34(1):54-60. PubMed ID: 18514151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone.
    Martin SD; Libretto SE; Pratt DJ; Brewin JS; Huq ZU; Saleh BT
    Curr Med Res Opin; 2003; 19(4):298-305. PubMed ID: 12841922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients.
    Baandrup L; Allerup P; Lublin H; Nordentoft M; Peacock L; Glenthoj B
    Acta Psychiatr Scand; 2010 Nov; 122(5):367-74. PubMed ID: 20456285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.